Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
Anti-malaria API facility will be operational in 15-18 months
It’s an AB-rated generic therapeutic version of Durezol
Demand normalisation post the second wave contributed to the steady growth
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Subscribe To Our Newsletter & Stay Updated
